1,25 OH vitamina D como mediador de hipercalcemia maligna: Reporte de caso
PDF (Español (España))
HTML (Español (España))


1,25 hidroxivitamina D
linfoma de Hodgkin

How to Cite

Altamar Ll., H., & Fernández, M. (2018). 1,25 OH vitamina D como mediador de hipercalcemia maligna: Reporte de caso. Revista Colombiana De Endocrinología, Diabetes &Amp; Metabolismo, 5(1), 41–43. https://doi.org/10.53853/encr.5.1.341


La hipercalcemia es una de las complicaciones metabólicas en pacientes con cáncer. A diferencia de lo que pasa en los adultos, la hipercalcemia en pacientes pediátricos es menos frecuente. Se reporta el caso de un paciente de 15 años con linfoma de Hodgkin, quien presentó hipercalcemia severa no mediada por paratohormona, con evolución favorable con las medidas de soporte y la terapia antineoplásica.

PDF (Español (España))
HTML (Español (España))


1. Grill V, Martin TJ. Hypercalcemia of malignancy. Rev Endocr Metab Disord. 2000;1(4):253-63.
2. Firkin F, Schneider H, Grill V. Parathyroid hormone-related protein in hypercalcemia associated with hematological malignancy. Leuk Lymphoma. 1998;29(5-6):499-506.
3. Minisola S, Pepe J, Piemonte S, Cipriani C. The diagnosis and management of hypercalcaemia. BMJ. 2015;350:h2723.
4. Davies JH. Approach to the Child with Hypercalcaemia. Endocr Dev. 2015;28:101-18.
5. Hind E, Wood P, Walker V, Davies J. The investigation of hypercalcaemia in children and adolescents. Horm Res. 2007;68(suppl 1):74.
6. Çullas ?larslan NE, ??klar Z, Berbero?lu M. Childhood sustained hypercalcemia: A diagnostic challenge. J Clin Res Pediatr Endocrinol. 2017.
7. Mallet E, Metabolism WGoC. Primary hyperparathyroidism in neonates and childhood. The French experience (1984-2004). Horm Res. 2008;69(3):180-8.
8. Tebben PJ, Singh RJ, Kumar R. Vitamin D-Mediated Hypercalcemia: Mechanisms, Diagnosis, and Treatment. Endocr Rev. 2016;37(5):521-47.
9. Sargent JT, Smith OP. Haematological emergencies managing hypercalcaemia in adults and children with haematological disorders. Br J Haematol. 2010;149(4):465-77.
10. Seymour JF, Gagel RF. Calcitriol: the major humoral mediator of hypercalcemia in Hodgkin’s disease and non-Hodgkin’s lymphomas. Blood. 1993;82(5):1383-94.
11. Hewison M, Kantorovich V, Liker HR, Van Herle AJ, Cohan P, Zehnder D, et al. Vitamin D-mediated hypercalcemia in lymphoma: evidence for hormone production by tumor-adjacent macrophages. J Bone Miner Res. 2003;18(3):579-82.
12. Donovan PJ, Achong N, Griffin K, Galligan J, Pretorius CJ, McLeod DS. PTHrP- mediated hypercalcemia: causes and survival in 138 patients. J Clin Endocrinol Metab. 2015;100(5):2024-9.
13. Rizzoli R, Thiébaud D, Bundred N, Pecherstorfer M, Herrmann Z, Huss HJ, et al. Serum parathyroid hormone-related protein levels and response to bisphosphonate treatment in hypercalcemia of malignancy. J Clin Endocrinol Metab. 1999;84(10):3545-50.
14. Niizuma H, Fujii K, Sato A, Fujiwara I, Takeyama J, Imaizumi M. PTHrP-independent hypercalcemia with increased proinflammatory cytokines and bone resorption in two children with CD19-negative precursor B acute lymphoblastic leukemia. Pediatr Blood Cancer. 2007;49(7):990-3.
15. Stewart AF. Clinical practice. Hypercalcemia associated with cancer. N Engl J Med. 2005;352(4):373-9.
16. Fencl F, Bláhová K, Schlingmann KP, Konrad M, Seeman T. Severe hypercalcemic crisis in an infant with idiopathic infantile hypercalcemia caused by mutation in CYP24A1 gene. Eur J Pediatr. 2013;172(1):45-9.

Authors must state that they reviewed, validated and approved the manuscript's publication.  Moreover, they must sign a model release that should be sent.  A copy may be reviewed here




Download data is not yet available.